Advertisement

Autologous mesenchymal stromal cells to support allogeneic hematopoietic stem cell engraftment in sickle cell disease

      Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for sickle cell disease (SCD), but for the majority of patients who lack a matched sibling donor, hematopoietic stem cell (HSC) engraftment remains a significant barrier. Based upon their dual function in promoting hematopoiesis and immunomodulation, mesenchymal stromal cells (MSCs) are an attractive cell-based therapy to modulate immunity and engraftment post-HCT. Studies have revealed limitations in approaches using cryopreserved, random donor MSCs expanded in FBS. This suggests that fresh, autologous MSCs expanded in human platelet-lysate could circumvent these limitations, thus increasing the potential of MSCs to enhance engraftment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect